Li-Ying Huang

Synthesis and characterizations of Ni-NiO nanoparticles on PDDA-modified graphene for oxygen reduction reaction

We are presenting our recent research results about the Ni-NiO nanoparticles on poly-(diallyldimethylammonium chloride)-modified graphene sheet (Ni-NiO/PDDA-G) nanocomposites prepared by the hydrothermal method at 90°C for 24 h. The Ni-NiO nanoparticles on PDDA-modified graphene sheets are measured by transmission electron microscopy (TEM), energy-dispersive X-ray spectroscopy (EDS), and selected area electron diffraction (SAED) pattern for exploring the structural evidence to apply in the electrochemical catalysts. The size of Ni-NiO nanoparticles is around 5 nm based on TEM observations. The X-ray diffraction (XRD) results show the Ni in the (012), (110), (110), (200), and (220) crystalline orientations, respectively. Moreover, the crystalline peaks of NiO are found in (111) and (220). The thermal gravimetric analysis (TGA) result represents the loading content of the Ni metal which is about 34.82 wt%. The electron spectroscopy for chemical analysis/X-ray photoelectron spectroscopy (ESCA/XPS) reveals the Ni0 to NiII ratio in metal phase. The electrochemical studies with Ni-NiO/PDDA-G in 0.5 M aqueous H2SO4 were studied for oxygen reduction reaction (ORR).

Novel pH-sensitive drug carriers of carboxymethyl-hexanoyl chitosan (Chitosonic® Acid) modified liposomes

In this study, novel hybrid nanocarriers composed of carboxymethyl-hexanoyl chitosan (Chitosonic® Acid, CA) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE)-liposomes were developed. CA was immobilized onto the DSPE-liposomes by EDC/NHS reaction using the carboxyl group of CA and the amino group of DSPE. The characteristics of the resultant CA-modified liposomes were evaluated by transmission electron microscopy, dynamic light scattering, zeta potential, FTIR spectroscopy, X-ray photoelectron spectroscopy, and contact angle measurement. The results show that the particle size and surface charge of the CA-modified liposomes varied with the concentration of CA, and exhibited pH-sensitive behavior. In vitro drug release studies demonstrated the sustained release behavior of the doxorubicin in the CA-modified liposomes, related to the rapid release in the free doxorubicin. Interestingly, the doxorubicin release rate from CA-modified liposomes was lower at higher pH values (pH 7.4) than at lower pH values (pH 4), indicating that the drug carrier displayed pH-sensitive released behavior. Furthermore, CA-modified liposomes exhibited no cytotoxicity toward the fibroblast cells (L-929 cells), suggesting an excellent biocompatibility. Fluorescence and confocal microscopy images showed good cellular internalization of the CA-modified liposomes into the cellular compartment. These results confirm that the novel CA-modified liposomes could respond to pH environment, which is promising for drug controlled release applications, especially in the field of cancer cell therapy (lower pH environments).

Magnetically triggered nanovehicles for controlled drug release as a colorectal cancer therapy

Magnetic silica core/shell nanovehicles presenting atherosclerotic plaque-specific peptide-1 (AP-1) as a targeting ligand (MPVA-AP1 nanovehicles) have been prepared through a double-emulsion method and surface modification. Amphiphilic poly(vinyl alcohol) was introduced as a polymer binder to encapsulate various drug molecules (hydrophobic, hydrophilic, polymeric) and magnetic iron oxide (Fe3O4) nanoparticles. Under a high-frequency magnetic field, magnetic carriers (diameter: ca. 50 nm) incorporating the anti-cancer drug doxorubicin collapsed, releasing approximately 80% of the drug payload, due to the heat generated by the rapidly rotating Fe3O4 nanoparticles, thereby realizing rapid and accurate controlled drug release. Simultaneously, the magnetic Fe3O4 themselves could also kill the tumor cells through a hyperthermia effect (inductive heating). Unlike their ungrafted congeners (MPVA nanovehicles), the AP1-grafted nanovehicles bound efficiently to colorectal cancer cells (CT26-IL4Rα), thereby displaying tumor-cell selectivity. The combination of remote control, targeted dosing, drug-loading flexibility, and thermotherapy and chemotherapy suggests that magnetic nanovehicles such as MPVA-AP1 have great potential for application in cancer therapy.

Nanohybrid structure analysis and biomolecule release behavior of polysaccharide-CDHA drug carriers

Nanoscaled polymer composites were prepared from polysaccharide chitosan (CS) and Ca-deficient hydroxyapatite (CDHA). CS-CDHA nanocomposites were synthesized by in situ precipitation at pH 9, and the CS-CDHA carriers were then fabricated by ionic cross-linking methods using tripolyphosphate and chemical cross-linking methods by glutaraldehyde and genipin. Certain biomolecules such as vitamin B12, cytochrome c, and bovine serum albumin were loaded into the CS-CDHA carriers, and their release behaviors were investigated. Furthermore, these CS-CDHA carriers were examined by transmission electron microscopy, electron spectroscopy for chemical analysis, and X-ray diffraction. The release behavior of the biomolecules was controlled by the CS/CDHA ratios and cross-linked agents. By increasing the concentration of CS and the concentration of the cross-linking agents, cross-linking within carriers increases, and the release rate of the biomolecules is decreased. Moreover, the release rate of the biomolecules from the CS-CDHA carriers at pH 4 was higher than that at pH 10, displaying a pH-sensitive behavior. Therefore, these CS-CDHA hydrogel beads may be useful for intelligent drug release and accelerate bone reconstruction.

Hemocompatibility and anti-fouling behavior of multilayer biopolymers immobilized on gold-thiolized drug-eluting cardiovascular stents

To solve the thrombosis and restenosis problem in cardiovascular stent implantation for cardiovascular artery disease, chondroitin 6-sulfate (ChS) with heparin (HEP) have been used as drug carrier layers and alternatively covalently bonded on gold (Au)-dimercaptosuccinic acid (DMSA)-thiolized cardiovascular metallic (SUS316 L stainless steel, SS) stents. Sirolimus, a model drug, was encapsulated in the ChS-HEP alternative layers. The behavior of the drug in releasing and suppressing the growth of smooth-muscle cells (SMCs) was evaluated with 5-layer CHS-HEP coating on the SS stents. Moreover, hemocompatibility of blood clotting time and platelet adhesion was performed. The results showed that the 5-layer ChS-HEP-modified SS stents displayed the greatest hemocompatibility, showing prolonged blood clotting time of the activated partial thrombin time (> 500 s) and less platelet adhesion to reduce thrombosis. Furthermore, sirolimus can be released continuously for more than 40 days with the 5-layer ChS-HEP coating and is beneficial for inhibiting the growth of SMCs; however, it does not affect the proliferation of endothelial cells, which can avoid restenosis formation. Therefore, the multilayers of ChS-HEP grafted onto the Au-DMSA-cardiovascular SS stents provide high potential for use as drug eluting stents.